EP
ZNTL icon

Essential Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Essential Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58
Closed -$67 – 2801
2025
Q2 		$67 Buy
+58
New +$76 ﹤0.01% 2118

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's ZNTL Position: Q3 2025 in Review

Essential Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 58 shares — an estimated $67 sold.

Essential Partners first reported a position in ZNTL in Q2 2025 and held it in 1 quarter. The position peaked at $67 in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • Essential Partners reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 58 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $67.
  • Essential Partners first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Zentalis Pharmaceuticals position peaked at $67 in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.